Ligelizumab Gets Breakthrough Tx Status for Chronic Spontaneous Urticaria
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E (IgE) antibody.
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E (IgE) antibody.
TMB-003 is a locally delivered formulation of sitaxsentan, a highly selective endothelin receptor antagonist.
A woman presents for evaluation of a rash affecting both feet that prevents her from walking properly because of pain.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
A woman requests the removal of an asymptomatic growth on her cheek that has been present for 1 year.
A 51-year-old woman requested removal of growths under both eyes. Can you make the correct diagnosis?
The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials that evaluated the efficacy and safety of Klisyri ointment in adults with AK on the face or scalp.
The randomized, double-blind, double-dummy, active-controlled Heads Up study included 692 patients aged 18 to 75 years with moderate to severe atopic dermatitis who are candidates for systemic therapy.
This slideshow shows drug information for Zilxi. Click here for the complete Zilxi monograph.
A 38-year-old woman presents with a rash affecting her legs. Can you make the correct diagnosis?